An innovative, FDA cleared, technology
based on low frequency soundwaves,
using true 3D acquisition.1

The National Cancer Institute, part of The National Institutes of Health (NIH) has awarded grants of over $15 million to fund the development of this technology and our clinical trials.
QTI’s Breast Acoustic CT™ Scanner has received FDA 510(k) marketing clearance for use as an ultrasonic imaging system of a patient’s breast. The device is not intended to be used as a replacement for screening mammography.
Dense breasts are common. In fact, about 50% of women in the US and more than 75% of women in Asia have dense breasts. With images that show clear information about breast tissue, our goal is to identify what is benign, and what’s problematic.
98% of recalls
are avoidable
Over 80% of callback
biopsies are benign 3
* Source: Mark Lenox et al. Imaging Performance of Quantitative Transmission Ultrasound, International Journal of Biomedical Imaging
1 Source: 3-D Nonlinear Acoustic Inverse Scattering: Algorithm and Quantitative Results, IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control
2 Source: Imaging Performance of Quantitative Transmission Ultrasound, International Journal of Biomedical Imaging
3 Source: Breast Biopsy: Procedure Types, What to Expect and Results, National Breast Cancer Foundation
4 Source: U.S. Breast Cancer Statistics, Breastcancer.org
B. Malik, R. Terry, J. Wiskin, and M. Lenox, Quantitative Transmission Ultrasound Tomography: Imaging and Performance Characteristics, Medical Physics, published 2019.